A phase II trial of nivolumab for patients with platinum-refractory recurrent or metastatic salivary gland cancer
This phase II trial of nivolumab for patients with platinum-refractory RM-SGC did not meet its primary endpoint of ORR. Although nivolumab may be worth further development in salivary duct carcinoma, these results may raise concerns over nivolumab monotherapy for RM-SGC.
Authors
- Takahiro Tsujikawa (ORCID: https://orcid.org/0000-0003-1647-342X)
- Yoshinori Imamura (ORCID: https://orcid.org/0000-0002-5202-531X)
- Yukinori Asada (ORCID: https://orcid.org/0000-0002-8955-7168)
- Ari Nishimura
- Naomi Kiyota (ORCID: https://orcid.org/0000-0001-8021-6116)
- Shiro Kimbara (ORCID: https://orcid.org/0000-0002-7743-7038)
- Yuji Hirayama
- Masaaki Higashino (ORCID: https://orcid.org/0000-0002-9905-5102)
- Hironaga Satake (ORCID: https://orcid.org/0000-0001-7629-6803)
- Taiji Koyama (ORCID: https://orcid.org/0000-0002-2893-605X)
- Yoshiaki Nagatani (ORCID: https://orcid.org/0009-0000-6153-6456)
- Katsunari Yane (ORCID: https://orcid.org/0009-0003-7990-4386)
- Takuma Onoe
- Shogen Boku (ORCID: https://orcid.org/0000-0002-5015-0379)
- Ken‐ichi Nibu (ORCID: https://orcid.org/0000-0002-5461-4871)
- Yohei Funakoshi (ORCID: https://orcid.org/0000-0001-7793-5013)
- Ichiro Ota (ORCID: https://orcid.org/0000-0003-3815-8877)
- Hikari Shimoda (ORCID: https://orcid.org/0000-0002-0274-2126)
- Hironobu Minami (ORCID: https://orcid.org/0000-0001-8630-9145)
- Tomoko Yamazaki
- Kaoru Tanaka (ORCID: https://orcid.org/0000-0002-4927-1368)
- Hirokazu Uemura (ORCID: https://orcid.org/0000-0001-7502-3619)
- Hajime Fujiwara
Institutions
- Kansai Medical University (JP)
- Kyoto Prefectural University of Medicine (JP)
- Kochi Medical School Hospital (JP)
- Kobe University Hospital (JP)
- Miyagi Prefectural Hospital Organization (JP)
- Saitama International Medical Center (JP)
- Hyogo Prefectural Cancer Center (JP)
- Nara Medical University (JP)
- Kobe University (JP)
- Kōchi University (JP)
- Saitama Medical University (JP)
- Osaka University of Pharmaceutical Sciences (JP)
- Kindai University (JP)
Publication Details
- Journal
- Japanese Journal of Clinical Oncology
- Published
- 2025-11-13
- DOI
- https://doi.org/10.1093/jjco/hyaf192
- Primary Topic
- Salivary Gland Tumors Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Bristol-Myers Squibb
- AstraZeneca
- Ministry of Education, Culture, Sports, Science and Technology
- Ono Pharmaceutical
- Chugai Pharmaceutical